Alembic Pharmaceuticals Limited's wholly owned subsidiary, Aleor Dermaceuticals Limited has received final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for docosanol cream, 10% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Abreva cream, 10% (OTC), of GlaxoSmithKline Consumer Healthcare. Docosanol cream, 10% (OTC) is used for cold sore/fever blisters on the face or lips. Docosanol cream, 10% (OTC) has an estimated market size of US$ 60 million for twelve months ending December 2021 according to IQVIA. Alembic has received a cumulative total of 166 ANDA approvals (142 final approvals and 24 tentative approvals) from US FDA. Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!